Pricing and Market Access Archives - Pharmaceutical Technology https://www.pharmaceutical-technology.com/sector/pricing-and-market-access/ The leading site for news and procurement in the pharmaceutical industry Fri, 05 Jan 2024 18:16:16 +0000 en-US hourly 1 https://wordpress.org/?v=6.4.2 https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2022/01/cropped-Pharmaceutical-Technology-Favicon-150x150.png Pricing and Market Access Archives - Pharmaceutical Technology https://www.pharmaceutical-technology.com/sector/pricing-and-market-access/ 32 32 Signal: UK online pharmacies selling prescription drugs without proper checks https://www.pharmaceutical-technology.com/news/signal-uk-online-pharmacies-selling-prescription-drugs-without-proper-checks/ https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/01/Benzos.jpg Fri, 05 Jan 2024 18:15:59 +0000 https://www.pharmaceutical-technology.com/news/signal-uk-online-pharmacies-selling-prescription-drugs-without-proper-checks/ Risk adjusted net present value: What is the current valuation of F. Hoffmann-La Roche’s Autogene cevumeran? https://www.pharmaceutical-technology.com/data-insights/autogene-cevumeran-f-hoffman-la-roche-net-present-value/ https://www.pharmaceutical-technology.com/data-insights/autogene-cevumeran-f-hoffman-la-roche-net-present-value/#respond Thu, 04 Jan 2024 16:24:33 +0000 https://www.pharmaceutical-technology.com/data-insights/autogene-cevumeran-f-hoffman-la-roche-net-present-value/feed/ 0 Pharmaceutical Technology Excellence Awards 2023: KAI Conversations https://www.pharmaceutical-technology.com/excellence-awards/featured-company/2023-kai/ https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/01/Kai-Logo.png Fri, 05 Jan 2024 10:59:55 +0000 https://www.pharmaceutical-technology.com/excellence-awards/featured-company/2023-kai/ Risk adjusted net present value: What is the current valuation of Alkermes’s Nemvaleukin alfa? https://www.pharmaceutical-technology.com/data-insights/nemvaleukin-alfa-alkermes-net-present-value/ https://www.pharmaceutical-technology.com/data-insights/nemvaleukin-alfa-alkermes-net-present-value/#respond Thu, 04 Jan 2024 16:23:45 +0000 https://www.pharmaceutical-technology.com/data-insights/nemvaleukin-alfa-alkermes-net-present-value/feed/ 0 TAC-101 by Triumvira Immunologics for Ovarian Cancer: Likelihood of Approval https://www.pharmaceutical-technology.com/data-insights/tac-101-triumvira-immunologics-ovarian-cancer-likelihood-of-approval/ https://www.pharmaceutical-technology.com/data-insights/tac-101-triumvira-immunologics-ovarian-cancer-likelihood-of-approval/#respond Thu, 04 Jan 2024 23:37:23 +0000 https://www.pharmaceutical-technology.com/data-insights/tac-101-triumvira-immunologics-ovarian-cancer-likelihood-of-approval/feed/ 0 U-01 by Shanghai Unicar-Therapy Bio-Medicine Technology for Refractory Acute Myeloid Leukemia: Likelihood of Approval https://www.pharmaceutical-technology.com/data-insights/u-01-shanghai-unicar-therapy-bio-medicine-technology-refractory-acute-myeloid-leukemia-likelihood-of-approval/ https://www.pharmaceutical-technology.com/data-insights/u-01-shanghai-unicar-therapy-bio-medicine-technology-refractory-acute-myeloid-leukemia-likelihood-of-approval/#respond Thu, 04 Jan 2024 19:48:56 +0000 https://www.pharmaceutical-technology.com/data-insights/u-01-shanghai-unicar-therapy-bio-medicine-technology-refractory-acute-myeloid-leukemia-likelihood-of-approval/feed/ 0 BPX-401 by Bellicum Pharmaceuticals for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval https://www.pharmaceutical-technology.com/data-insights/bpx-401-bellicum-pharmaceuticals-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ https://www.pharmaceutical-technology.com/data-insights/bpx-401-bellicum-pharmaceuticals-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/#respond Thu, 04 Jan 2024 17:38:34 +0000 https://www.pharmaceutical-technology.com/data-insights/bpx-401-bellicum-pharmaceuticals-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/feed/ 0 Elamipretide hydrochloride by Stealth BioTherapeutics for Dry (Atrophic) Macular Degeneration: Likelihood of Approval https://www.pharmaceutical-technology.com/data-insights/elamipretide-hydrochloride-stealth-biotherapeutics-dry-atrophic-macular-degeneration-likelihood-of-approval/ https://www.pharmaceutical-technology.com/data-insights/elamipretide-hydrochloride-stealth-biotherapeutics-dry-atrophic-macular-degeneration-likelihood-of-approval/#respond Thu, 04 Jan 2024 17:05:28 +0000 https://www.pharmaceutical-technology.com/data-insights/elamipretide-hydrochloride-stealth-biotherapeutics-dry-atrophic-macular-degeneration-likelihood-of-approval/feed/ 0 Osteoarthritis by Purecell Group for Osteoarthritis: Likelihood of Approval https://www.pharmaceutical-technology.com/data-insights/osteoarthritis-purecell-group-osteoarthritis-likelihood-of-approval/ https://www.pharmaceutical-technology.com/data-insights/osteoarthritis-purecell-group-osteoarthritis-likelihood-of-approval/#respond Fri, 05 Jan 2024 00:44:56 +0000 https://www.pharmaceutical-technology.com/data-insights/osteoarthritis-purecell-group-osteoarthritis-likelihood-of-approval/feed/ 0 ILYX-002 by Iolyx Therapeutics for Keratoconjunctivitis Sicca (Dry Eye): Likelihood of Approval https://www.pharmaceutical-technology.com/data-insights/ilyx-002-iolyx-therapeutics-keratoconjunctivitis-sicca-dry-eye-likelihood-of-approval/ https://www.pharmaceutical-technology.com/data-insights/ilyx-002-iolyx-therapeutics-keratoconjunctivitis-sicca-dry-eye-likelihood-of-approval/#respond Fri, 05 Jan 2024 00:44:38 +0000 https://www.pharmaceutical-technology.com/data-insights/ilyx-002-iolyx-therapeutics-keratoconjunctivitis-sicca-dry-eye-likelihood-of-approval/feed/ 0 Triple Combination Therapy by Novartis for Malaria: Likelihood of Approval https://www.pharmaceutical-technology.com/data-insights/triple-combination-therapy-novartis-malaria-likelihood-of-approval/ https://www.pharmaceutical-technology.com/data-insights/triple-combination-therapy-novartis-malaria-likelihood-of-approval/#respond Fri, 05 Jan 2024 00:44:21 +0000 https://www.pharmaceutical-technology.com/data-insights/triple-combination-therapy-novartis-malaria-likelihood-of-approval/feed/ 0 Brainshuttle (BS) CD20-Multiple Sclerosis by Genentech USA for Multiple Sclerosis: Likelihood of Approval https://www.pharmaceutical-technology.com/data-insights/brainshuttle-bs-cd20-multiple-sclerosis-genentech-usa-multiple-sclerosis-likelihood-of-approval/ https://www.pharmaceutical-technology.com/data-insights/brainshuttle-bs-cd20-multiple-sclerosis-genentech-usa-multiple-sclerosis-likelihood-of-approval/#respond Fri, 05 Jan 2024 00:44:03 +0000 https://www.pharmaceutical-technology.com/data-insights/brainshuttle-bs-cd20-multiple-sclerosis-genentech-usa-multiple-sclerosis-likelihood-of-approval/feed/ 0 JNJ-88549968 by Johnson & Johnson for Myeloproliferative Disorders: Likelihood of Approval https://www.pharmaceutical-technology.com/data-insights/jnj-88549968-johnson-johnson-myeloproliferative-disorders-likelihood-of-approval/ https://www.pharmaceutical-technology.com/data-insights/jnj-88549968-johnson-johnson-myeloproliferative-disorders-likelihood-of-approval/#respond Fri, 05 Jan 2024 00:43:46 +0000 https://www.pharmaceutical-technology.com/data-insights/jnj-88549968-johnson-johnson-myeloproliferative-disorders-likelihood-of-approval/feed/ 0 SGN-516 by SGN Nanopharma for Diabetic Neuropathy: Likelihood of Approval https://www.pharmaceutical-technology.com/data-insights/sgn-516-sgn-nanopharma-diabetic-neuropathy-likelihood-of-approval/ https://www.pharmaceutical-technology.com/data-insights/sgn-516-sgn-nanopharma-diabetic-neuropathy-likelihood-of-approval/#respond Fri, 05 Jan 2024 00:43:29 +0000 https://www.pharmaceutical-technology.com/data-insights/sgn-516-sgn-nanopharma-diabetic-neuropathy-likelihood-of-approval/feed/ 0 MP-204 by Mustafa Nevzat Ilac ve Kimyevi Maddeler San Tic for Human Papillomavirus Infections: Likelihood of Approval https://www.pharmaceutical-technology.com/data-insights/mp-204-mustafa-nevzat-ilac-ve-kimyevi-maddeler-san-tic-human-papillomavirus-infections-likelihood-of-approval/ https://www.pharmaceutical-technology.com/data-insights/mp-204-mustafa-nevzat-ilac-ve-kimyevi-maddeler-san-tic-human-papillomavirus-infections-likelihood-of-approval/#respond Fri, 05 Jan 2024 00:43:12 +0000 https://www.pharmaceutical-technology.com/data-insights/mp-204-mustafa-nevzat-ilac-ve-kimyevi-maddeler-san-tic-human-papillomavirus-infections-likelihood-of-approval/feed/ 0 ST-617 by Supportive Therapeutics for Chemotherapy Induced Oral Mucositis: Likelihood of Approval https://www.pharmaceutical-technology.com/data-insights/st-617-supportive-therapeutics-chemotherapy-induced-oral-mucositis-likelihood-of-approval/ https://www.pharmaceutical-technology.com/data-insights/st-617-supportive-therapeutics-chemotherapy-induced-oral-mucositis-likelihood-of-approval/#respond Fri, 05 Jan 2024 00:42:55 +0000 https://www.pharmaceutical-technology.com/data-insights/st-617-supportive-therapeutics-chemotherapy-induced-oral-mucositis-likelihood-of-approval/feed/ 0 TBO-309 by Heart Research Institute for Acute Ischemic Stroke: Likelihood of Approval https://www.pharmaceutical-technology.com/data-insights/tbo-309-heart-research-institute-acute-ischemic-stroke-likelihood-of-approval/ https://www.pharmaceutical-technology.com/data-insights/tbo-309-heart-research-institute-acute-ischemic-stroke-likelihood-of-approval/#respond Fri, 05 Jan 2024 00:42:36 +0000 https://www.pharmaceutical-technology.com/data-insights/tbo-309-heart-research-institute-acute-ischemic-stroke-likelihood-of-approval/feed/ 0 (Ceftibuten + xeruborbactam) by Qpex Biopharma for Pyelonephritis: Likelihood of Approval https://www.pharmaceutical-technology.com/data-insights/ceftibuten-xeruborbactam-qpex-biopharma-pyelonephritis-likelihood-of-approval/ https://www.pharmaceutical-technology.com/data-insights/ceftibuten-xeruborbactam-qpex-biopharma-pyelonephritis-likelihood-of-approval/#respond Fri, 05 Jan 2024 00:42:18 +0000 https://www.pharmaceutical-technology.com/data-insights/ceftibuten-xeruborbactam-qpex-biopharma-pyelonephritis-likelihood-of-approval/feed/ 0 Pneumococcal (monovalent) vaccine by Pfizer for Streptococcal Pneumonia: Likelihood of Approval https://www.pharmaceutical-technology.com/data-insights/pneumococcal-monovalent-vaccine-pfizer-streptococcal-pneumonia-likelihood-of-approval/ https://www.pharmaceutical-technology.com/data-insights/pneumococcal-monovalent-vaccine-pfizer-streptococcal-pneumonia-likelihood-of-approval/#respond Fri, 05 Jan 2024 00:42:01 +0000 https://www.pharmaceutical-technology.com/data-insights/pneumococcal-monovalent-vaccine-pfizer-streptococcal-pneumonia-likelihood-of-approval/feed/ 0 BGB-43395 by BeiGene for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval https://www.pharmaceutical-technology.com/data-insights/bgb-43395-beigene-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ https://www.pharmaceutical-technology.com/data-insights/bgb-43395-beigene-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/#respond Fri, 05 Jan 2024 00:41:44 +0000 https://www.pharmaceutical-technology.com/data-insights/bgb-43395-beigene-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/feed/ 0